Nomura Sticks to Their Buy Rating for Sarepta Therapeutics (SRPT)

By Carrie Williams

In a report issued on December 23, Christopher Marai from Nomura maintained a Buy rating on Sarepta Therapeutics (SRPTResearch Report), with a price target of $230.00. The company’s shares closed last Monday at $134.30.

According to TipRanks.com, Marai is a 4-star analyst with an average return of 6.6% and a 51.6% success rate. Marai covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Protagonist Therapeutics, and Alexion Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Sarepta Therapeutics with a $202.65 average price target, which is a 49.3% upside from current levels. In a report issued on December 13, Piper Jaffray also reiterated a Buy rating on the stock with a $210.00 price target.

See today’s analyst top recommended stocks >>

Based on Sarepta Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $126 million. In comparison, last year the company had a GAAP net loss of $76.39 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.